Trials / Recruiting
RecruitingNCT06509503
Impact of Combined Oral Contraceptive Pills on Migraine
Impact of Combined Oral Contraceptive Pills on Migraine, a Randomized Controlled Trial
- Status
- Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 400 (estimated)
- Sponsor
- Kafrelsheikh University · Academic / Other
- Sex
- Female
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
The investigators will assess the effect of combined oral contraceptive pills (COCs) on migraine features and treatment response to allow better interpretation of the exact consequence of hormonal contraceptive use on migraineurs.
Detailed description
The investigators will use a questionnaire to detect the migraineur demographic and clinical features (disease duration, attack frequency and duration, pain intensity assessed by visual analogic scale, HIT score in female patients on regular COCs * Special emphasis was put on clinical phenotype (for example, the character of pain, location, associated symptoms, etc.); vascular risk factors (hypertension, diabetes, smoking); history of cerebrovascular events and other conditions (collagen disorders, hepatic disorders, blood diseases, heart, kidneys), and family history. * All the patients will undergo clinical neurological and general physical examinations, and migraine history and associated phenotypic features will be established.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Combined oral contraceptive | The arm will include 200 migraine patients diagnosed according to ICHD3-beta criteria. The patients are regular users of COCs and will receive propranolol 80-160mg daily and ibuprofen 200-400 mg only in acute migraine attacks for 3 months. |
| DRUG | Vaginal Ring | The arm will include 200 migraine patients diagnosed according to ICHD3-beta criteria. The patients are users of mechanical contraceptive methods and will receive propranolol 80-160mg daily and ibuprofen 200-400 mg only in acute migraine attacks for 3 months. |
Timeline
- Start date
- 2024-07-15
- Primary completion
- 2025-05-15
- Completion
- 2025-07-30
- First posted
- 2024-07-19
- Last updated
- 2024-10-09
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT06509503. Inclusion in this directory is not an endorsement.